Assisted Reproductive Technology Market Hits USD 179.4 Billion by 2032

Introduction

The Global Assisted Reproductive Technology (ART) Market is experiencing significant growth, driven by advancements in medical technologies and increasing awareness about fertility treatments. In 2022, the market size was valued at USD 31.85 billion and is projected to reach approximately USD 179.4 billion by 2032, exhibiting a robust compound annual growth rate (CAGR) of 19.4% during the forecast period. This growth can be attributed to several factors, including the rising prevalence of infertility, technological advancements such as cryopreservation and preimplantation genetic diagnosis, and increased support from government initiatives aimed at improving access to fertility treatments.

Challenges facing the ART market include high treatment costs, ethical concerns surrounding procedures like egg and sperm donation, and the physical and emotional demands on patients undergoing these treatments. Despite these challenges, the market continues to expand, supported by ongoing research and development, which has led to improved success rates and more accessible treatment options.

Recent developments in the market include significant investments and expansions by major players. For instance, in 2022, FUJIFILM Irvine Scientific launched a new product, Heavy Oil for Embryo Culture, enhancing the efficiency and safety of IVF procedures. Additionally, CooperSurgical’s acquisition of Embryo Options and Hamilton Throne’s purchase of IVFTECH ApS highlight the industry’s focus on expanding capabilities and improving patient outcomes through technological innovation and strategic partnerships.

Overall, the assisted reproductive technology market is poised for substantial growth, fueled by advancements in medical science, increased awareness, and supportive government policies.

Key Takeaways

• The global assisted reproductive technology (ART) market is expanding at a CAGR of 19.4% from 2023 to 2032.
• Accessory and disposable-type ART dominated the market in 2022, holding the largest share at 52.3%.
• In-vitro fertilization (IVF) was the most lucrative technology segment in 2022, with an 87% market share.
• Fresh non-donor procedures were the most profitable in 2022, representing 40% of the market.
• Fertility clinics were the leading end-users, contributing 40.5% to the ART market in 2022.
• Technological advancements, such as IVF and ICSI, have significantly improved ART success rates.
• Rising disposable incomes have made ART more accessible to a broader population.
• Increased awareness and government support are driving higher demand for ART services.
• Europe was the most lucrative ART market in 2022, with a 39.2% market share.
• The Asia Pacific region is experiencing rapid growth in ART due to rising awareness and demand.

Assisted Reproductive Technology Statistics

• In 2022, 91,771 babies were born through IVF, representing 2.5% of US births and showing a 2.5% increase from 2021.
• ART cycles increased by 6% to 389,993, indicating rising demand for fertility services despite legislative challenges.
• Egg-freezing cycles surged to 29,803 in 2022, up from 24,560 in 2021, reflecting evolving patient choices and needs.
• Elective single embryo transfer (eSET) usage increased, reducing multiple births from 5% to 4%.
• In 2022, 73.9% of cycles involved single embryo transfer, promoting safer and healthier pregnancies.
• Nearly 96% of ART babies born in 2022 were singletons, a significant rise from 80% in 2015.
• Live birth rates per intended egg retrieval by age were: under 35: 43.1%, 35-37: 31%, 38-40: 19%, over 42: 3.2%.
• In 2021, approximately 238,126 patients underwent 413,776 assisted reproductive technology (ART) cycles across 453 clinics in the United States.
• These ART cycles led to 91,906 live births, resulting in the birth of 97,128 live-born infants.
• Of the ART cycles, 167,689 involved the banking of eggs or embryos for future use.
• In 2006, U.S. fertility clinics performed over 140,000 ART procedures, resulting in 55,000 births.
• Initial fertility workup costs range from $3,100 to $1,600 for procedures like hysteroscopy and sonohysterogram.
• A single IVF cycle in the U.S. costs between $15,600 and $46,800.
• Insurance coverage for fertility treatments leads to a 278% higher usage rate in states with mandated coverage.
• In 2015, 157,500 children were born using ART in Europe, with varying legislation across countries.
• Spain opened ART to all women in 1977, while France granted the same right in 2019.
• Israel’s national health insurance covers nearly all fertility treatments, including IVF, for up to two children.
• In Canada, some provinces partially cover fertility treatments, but most costs are borne by patients.
• India regulates ART practices through the Surrogacy and Assisted Reproductive Technology Acts, recognizing single women’s rights to ART.
• The first successful IVF birth was Louise Brown on July 25, 1978, in England.
• Intracytoplasmic Sperm Injection (ICSI) led to its first successful birth on January 14, 1992, revolutionizing ART.
• Around 10% of women aged 15–44 in the US have difficulty either conceiving or maintaining a pregnancy, highlighting significant fertility challenges faced by this demographic.
• Globally, 8–12% of couples face fertility issues, with male factors contributing to 40–50% of these cases, underscoring the need for comprehensive reproductive health solutions.
• Approximately 1.9% of infants born in the US are conceived using Assisted Reproductive Technology (ART), reflecting the increasing reliance on these advanced medical procedures.
• According to the CDC, In Vitro Fertilization with Embryo Transfer (IVF-ET) accounts for 99% of all ART procedures, indicating its predominant use in fertility treatments.
• For individuals aged 35 or younger, the success rate of IVF for one oocyte retrieval stands at 52%, offering promising outcomes for this age group.
• The IVF success rate declines to 38.1% for individuals aged 35–37, showing a notable decrease in effectiveness with advancing age.
• Those aged 38–40 experience a further drop in IVF success rates to 23.5%, highlighting the increased challenges faced by this age group.
• For individuals over 40, the success rate of IVF falls significantly to 7.6%, emphasizing the impact of age on fertility treatment outcomes.
• In 2017, 52% of individuals undergoing Frozen Embryo Transfer (FET) had ongoing pregnancies, showcasing the potential success of this procedure.
• Intracytoplasmic Sperm Injection (ICSI) achieves fertilization rates between 50–80%, making it a crucial technique in assisted reproduction.
• Approximately 50% of embryo transfers using donated frozen embryos result in pregnancy, highlighting the effectiveness of this approach.
• Of these embryo transfers, about 40% lead to a live birth, indicating a substantial success rate for achieving full-term pregnancies.
• The average cost of a single IVF cycle ranges from $12,000 to $17,000, reflecting the significant financial investment required for this treatment.
• Frozen Embryo Transfer (FET) procedures can cost up to $6,000, adding to the overall expense of fertility treatments.
• Sperm donation typically costs around $1,000 per vial, making it a relatively affordable option within assisted reproductive technologies.
• Egg donation costs range from $18,000 to $50,000, representing a considerable financial commitment for prospective parents.
• Embryo adoption expenses are generally between $13,000 and $17,000, offering an alternative route for individuals seeking to expand their families.
• Surrogacy and the use of gestational carriers can cost between $60,000 and $150,000, reflecting the high financial stakes involved in these arrangements.
• Ethical considerations in fertility treatments include issues like the necessity of procedures, ownership of gametes, religious beliefs, age limits, and the disclosure of genetic parentage.
• The use of gametes from deceased individuals raises complex ethical questions, necessitating careful consideration of the implications involved.
• In 2021, 86,146 infants were born through ART, making up 2.3% of the 3,683,596 total births in the United States.
• For women under 35, the single embryo transfer rate was 85.8%; for those aged 35-37, it was 85.1%; for women aged 38-40, it was 80.3%; and for women over 40, it was 76.8%.
• Approximately 12.5% of infants born through ART were multiples, including twins, triplets, or more.
• Low birth weight was observed in 14.7% of ART infants, higher than the 8.5% seen in the overall birth population.
• Preterm births were recorded in 19.7% of ART infants, significantly higher than the 10.5% preterm birth rate in the general birth population.

Assisted Reproductive Technology (ART) in Japan

• In 2021, there were 625 ART facilities in Japan, conducting a total of 498,140 registered treatment cycles.
• The number of neonates born from ART in 2021 was 69,797, reflecting a 15.5% increase from the previous year.
• The total treatment cycles increased by 10.7% from the previous year, reaching 498,140 in 2021.
• Japan recorded 42,016 freeze-all IVF cycles in 2021, contributing significantly to the ART treatment landscape.
• IVF-embryo transfer (ET) cycles resulted in 2,268 neonates, showing the impact of this specific ART method.
• Intracytoplasmic sperm injection (ICSI) cycles totaled 170,350 in 2021, with 2,850 neonates born from these cycles.
• Frozen-thawed embryo transfer (FET) cycles increased by 11.2% from 2020, reaching 239,428 cycles in 2021.
• There were 87,174 pregnancies resulting from FET cycles, demonstrating the effectiveness of this ART approach.
• A total of 64,679 neonates were born from FET cycles, highlighting the success rate of frozen-thawed embryo transfers.
• Singleton pregnancy rates for fresh transfers were 97.0%, while the singleton live birth rate was 97.3%.
• For frozen-thawed embryo transfers (FET), the singleton pregnancy rate was 96.9%, and the singleton live birth rate was 97.1%.
• The mean patient age for registered ART cycles was 37.8 years, indicating the demographic profile of ART patients.
• Women aged 40 or over accounted for 39.9% of ART cycles, showing a significant proportion of older patients seeking treatment.
• Pregnancy rates per embryo transfer for IVF stood at 23.6%, reflecting the chances of success for each transfer.
• The pregnancy rate per embryo transfer for ICSI was 18.8%, indicating the effectiveness of this technique.
• FET cycles had a pregnancy rate per embryo transfer of 36.9%, showing a higher success rate compared to fresh transfers.
• The miscarriage rate per pregnancy for FET cycles was 24.8%, highlighting the challenges faced during the process.
• The live birth rate per FET was 26.6%, illustrating the final success rate of these cycles.
• Trends indicate declining pregnancy rates with increasing maternal age, especially beyond 40 years, underscoring age-related challenges in ART success.

Emerging Trends

• Cryopreservation Advancements: Cryopreservation techniques have significantly advanced, particularly with the use of vitrification. Unlike slow freezing, vitrification rapidly turns biological material into a glass-like state, which enhances preservation and viability. This method has notably increased the success rates of pregnancies from frozen eggs and embryos. The rapid cooling process prevents the formation of ice crystals, which can damage cells. These improvements in vitrification have made it a preferred method for preserving reproductive cells, contributing to higher success rates in assisted reproductive technology (ART) procedures.
• In-Vitro Fertilization (IVF) Enhancements: Since its inception, IVF has seen continuous evolution and innovation. Techniques such as intracytoplasmic sperm injection (ICSI) and optimized embryo transfer have significantly improved success rates. ICSI involves the direct injection of a single sperm into an egg, enhancing fertilization rates. Additionally, assisted hatching and preimplantation genetic testing (PGT) have contributed to better outcomes. Assisted hatching helps the embryo implant into the uterine wall, while PGT screens for genetic abnormalities, ensuring healthier embryos. These advancements collectively enhance the efficacy and success rates of IVF treatments.
• INVOcell Technology: INVOcell presents a cost-effective alternative to traditional IVF by allowing embryos to develop within a woman’s body instead of an incubator. This method not only reduces costs but also provides a more natural environment for embryo development. By using the body’s natural conditions, INVOcell can potentially enhance the success rates of embryo development and implantation. The process involves placing eggs and sperm into a small device, which is then inserted into the woman’s body, where fertilization and early embryo development occur, offering a more patient-friendly approach to fertility treatment.
• Endometrial Receptivity Array (ERA): The Endometrial Receptivity Array (ERA) test is a breakthrough in determining the optimal timing for embryo implantation. This test analyzes gene expression in endometrial tissue to identify the best window for implantation. By pinpointing this precise timing, the ERA test helps increase the chances of successful implantation and pregnancy. The test involves taking a small sample of endometrial tissue, which is then analyzed to assess the receptivity of the endometrium. This personalized approach to timing embryo transfer can significantly improve ART outcomes by ensuring embryos are implanted when the endometrium is most receptive.
• Artificial Intelligence (AI) Integration: Artificial Intelligence (AI) is becoming increasingly integrated into fertility clinics to enhance ART procedures. AI aids in embryo selection by analyzing large datasets to predict which embryos have the highest chance of leading to a successful pregnancy. Additionally, AI helps predict success rates and optimize treatment plans, making ART procedures more efficient and effective. By providing data-driven insights, AI can improve decision-making processes in fertility treatments, leading to higher efficiency and better patient outcomes. The integration of AI represents a significant step forward in the use of technology to improve fertility treatment success rates.

Use Cases

• Infertility Treatment: Assisted Reproductive Technology (ART), particularly In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI), plays a pivotal role in treating infertility. According to the World Health Organization, around 10-15% of couples worldwide experience infertility. ART offers these couples a viable option to conceive when other treatments fail. By combining egg and sperm outside the body, and then implanting the resulting embryo into the uterus, ART provides a chance to overcome various infertility issues. This method has become a cornerstone of infertility treatment, offering hope to many who face the challenges of conceiving naturally.
• Cancer Patients: For cancer patients, cryopreservation of eggs, sperm, and embryos before treatment is a vital fertility preservation option. Cancer therapies such as chemotherapy and radiation can significantly impair fertility. By preserving their gametes, patients secure the possibility of having biological children in the future. This process involves freezing and storing eggs, sperm, or embryos for later use, allowing cancer survivors to focus on their recovery without the additional concern of potential infertility. This approach ensures that patients have the opportunity to start or expand their families once they are healthy again.
• Single Mothers and Same-Sex Couples: Assisted Reproductive Technology (ART) has become a crucial option for single women and same-sex couples wishing to have biological children. With increasing social acceptance and legal support, the use of ART in these demographics is on the rise. Single women can use donor sperm, while same-sex couples can opt for donor gametes and surrogacy to achieve parenthood. ART offers these individuals and couples the opportunity to experience the joys of raising a child who shares their genetic heritage. This growing trend reflects broader changes in societal attitudes towards diverse family structures.
• Genetic Screening: Preimplantation Genetic Testing (PGT) is a sophisticated technique used in ART to screen embryos for genetic disorders before implantation. This process involves analyzing embryos to identify any genetic abnormalities, ensuring that only healthy embryos are selected for transfer to the uterus. By reducing the risk of inherited genetic diseases, PGT offers couples greater confidence in achieving a successful and healthy pregnancy. This screening is particularly beneficial for those with a family history of genetic conditions or recurrent pregnancy losses, providing a proactive approach to creating healthier families.

Conclusion

The Assisted Reproductive Technology (ART) market is set for substantial growth, driven by advancements in medical technologies and rising infertility rates globally. Despite challenges such as high treatment costs and ethical concerns, the market benefits from increasing awareness and government support. Key innovations, like cryopreservation and AI integration, continue to enhance success rates and accessibility. Major players are investing heavily in research and development, expanding capabilities, and forming strategic partnerships. With a projected CAGR of 19.4% from 2023 to 2032, the ART market is expected to reach approximately USD 179.4 billion by 2032, reflecting the critical role of technological advancements and supportive policies in driving market expansion.

Discuss Your Needs With Our Analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF